Trial · NCT04349072
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 | Mavacamten | 10 | Participants | ||
| Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 | Placebo to Mavacamten | 43 | Participants | ||
| Number of Participants With at Least One Class Improvement From Baseline in New York Heart Association (NYHA) Class at Week 16 | Mavacamten | 35 | Participants | ||
| Number of Participants With at Least One Class Improvement From Baseline in New York Heart Association (NYHA) Class at Week 16 | Placebo to Mavacamten | 12 | Participants | ||
| Change From Baseline to Week 16 in Kansas City Cardiomyopathy Questionnaire 23-item Version, Clinical Summary Score (KCCQ-23, CSS) | Mavacamten | 10.4 | Standard Deviation 16.06 | Score on a scale | |
| Change From Baseline to Week 16 in Kansas City Cardiomyopathy Questionnaire 23-item Version, Clinical Summary Score (KCCQ-23, CSS) | Placebo to Mavacamten | 1.8 | Standard Deviation 12.01 | Score on a scale | |
| Change From Baseline to Week 16 in N-Terminal Pro-b-Type Natriuretic Peptide (NT-proBNP) | Mavacamten | 0.35 | Geometric Coefficient of Variation NA | ng/L | |
| Change From Baseline to Week 16 in N-Terminal Pro-b-Type Natriuretic Peptide (NT-proBNP) | Placebo to Mavacamten | 1.13 | Geometric Coefficient of Variation NA | ng/L | |
| Change From Baseline to Week 16 in Cardiac Troponin | Mavacamten | 0.50 | Geometric Coefficient of Variation NA | ng/L | |
| Change From Baseline to Week 16 in Cardiac Troponin | Placebo to Mavacamten | 1.03 | Geometric Coefficient of Variation NA | ng/L | |
| Change From Baseline to Week 16 in Post-Exercise Left Ventricular Outflow Tract (LVOT) Gradient | Mavacamten | -39.1 | Standard Deviation 36.51 | mmHg | |
| Change From Baseline to Week 16 in Post-Exercise Left Ventricular Outflow Tract (LVOT) Gradient | Placebo to Mavacamten | -1.8 | Standard Deviation 28.82 | mmHg |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04349072/results